Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBT (2016 - 2025)

Historic EBT for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to -$1.9 million.

  • Cumberland Pharmaceuticals' EBT fell 2739.05% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year increase of 6868.1%. This contributed to the annual value of -$6.5 million for FY2024, which is 288.6% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported EBT of -$1.9 million as of Q3 2025, which was down 2739.05% from -$729536.0 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' EBT registered a high of $1.3 million during Q1 2025, and its lowest value of -$6.3 million during Q4 2023.
  • In the last 5 years, Cumberland Pharmaceuticals' EBT had a median value of -$1.4 million in 2022 and averaged -$1.3 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 115512.1% in 2024, then surged by 16630.53% in 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBT (Quarter) stood at -$4.4 million in 2021, then surged by 44.88% to -$2.4 million in 2022, then plummeted by 160.29% to -$6.3 million in 2023, then soared by 68.8% to -$2.0 million in 2024, then grew by 0.78% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$729536.0 for Q2 2025, and $1.3 million during Q1 2025.